The COVID-19 pandemic has highlighted the need for remote testing in patients with cognitive disorders. Combinostics is working on a web-based cognitive test tool, cCOG. The tool is currently for research use only.
Date: 02 September 2020
Combinostics and Alzheimer Center Amsterdam, Amsterdam UMC , publish a validation study of new self-administrable web-based cognitive test tool, cCOG
Together with the Alzheimer Center Amsterdam, Amsterdam UMC, Combinostics has published a peer reviewed validation study of the new cCOG tool for the early detection or neurodegenerative disorders. Led by Dr Hanneke Rhodius, the study found that cCOG is comparable to traditional pen and paper neuropsychology tests in detecting MCI and dementias.
cCOG was tested on almost five hundred patients from the Netherlands, Denmark, Finland and Italy who have memory problems. Patients took traditional pen and paper neuropsychology tests, as well as cCOG which was performed both in the clinical setting and at home for comparison. The study shows that cCOG performed just as accurately as the traditional neuropsychology tests, and test parameters have “strong correlation” to traditional neuropsychological tests.
“The online test consists of seven short tests, which resemble the standard traditional memory tests, so doctors can easily understand the results. I expect that in the (near) future doctors will use these kinds of tests to recognize dementia.” Hanneke Rhodius
The computerized global cognitive score constructed from the cCOG computerised test battery was found to be comparable to the global cognitive score produced by combining results from traditional neuropsychology tests, which is considered the gold standard.
The comparison against administration of cCOG in the clinical setting and in the home environment found that accuracy was comparatively consistent. This is a substantial development as the ability to complete neuropsychology testing at home not only makes testing more accessible to patients but is also crucial during times such as the current COVID-19 global pandemic when patients are not able to attend in person. Furthermore, the increased availability of this testing means that changes in cognition can be detected sooner leading to the faster commencement of treatment.
The Alzheimer Center Amsterdam, Amsterdam UMC, is at the international forefront of research into dementia. The center is constantly committed to improving diagnostics and treatment.
This work has received funding from the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 611005 (PredictND) and no. 601055 (VPH-DARE@IT). This collaboration is also co-funded by the PPP Allowance made available by Health-Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. Additional financing has been obtained through contributions from health funds.